Hindalco - basics

20 Sep 1999

1
 

Hindalco addresses: Registered office Century Bhavan, III floor, Dr. Annie Besant Road, Mumbai - 400 025 Tel: 91-22-4308491, 92, 93 Fax: 91-22-4227586

Principal office & works P.O. Renukoot - 231217 Dist. Sonbhdra, Uttar Pradesh Tel.: 91-5446-52077 - 9 Fax: 91-5446-52107

Renusagar power division P.O. Renusagar, Dist. Sonbhdra, Uttar Pradesh Tel.: 91-5446-72501 - 5 Fax: 91-5446-72382 Foil and wheels division Village Khutli, Khanvel, Silvassa - 396 230 U T of Dadra & Nagar Haveli Tel.: 91-2638-47221 Fax: 91-2638-42936

Investor correspondence cell The Company Secretary, Hindalco Industries Ltd. Century Bhavan, III floor, Dr. Annie Besant Road, Mumbai - 400 025 Tel.: 91-22-4308491/92/93 Fax: 91-22-422-7586 E-mail: hindalco.bby@rmj.sprintrpg.ems.vsnl.net.in

 

Latest articles

Sigma Advanced to acquire UK aerospace supplier Bromford for ₹153 crore

Sigma Advanced to acquire UK aerospace supplier Bromford for ₹153 crore

Akasa Air plans ₹1,050 crore fundraising to support growth amid higher costs

Akasa Air plans ₹1,050 crore fundraising to support growth amid higher costs

AI startup Reflection signs over $1 billion computing deal with Nebius

AI startup Reflection signs over $1 billion computing deal with Nebius

Tata Power explores $450 million overseas loan for business operations

Tata Power explores $450 million overseas loan for business operations

TCS wins technology contract for New York JFK Airport’s $19 billion terminal

TCS wins technology contract for New York JFK Airport’s $19 billion terminal

South Korean firms unveil $195 billion investment in AI and advanced industries

South Korean firms unveil $195 billion investment in AI and advanced industries

HCLTech wins $1.14 billion AI transformation deal with European client

HCLTech wins $1.14 billion AI transformation deal with European client

Microsoft launches Frontier to help enterprises accelerate AI adoption

Microsoft launches Frontier to help enterprises accelerate AI adoption

AstraZeneca signs up to $1.77 billion CSPC deal for kidney disease drugs

AstraZeneca signs up to $1.77 billion CSPC deal for kidney disease drugs